Hatch Medical Enters Into An Exclusive Brokerage Relationship with Fixit Medical to Broker Novel Percutaneous Drainage Catheter Fixation Device Cingo

February 2, 2021

Hatch Medical, L.L.C. notes the exclusive brokerage relationship is with inventor and CEO, Dr. Robert Ward, MB BS FRCS FRCR, and his company, Fixit Medical, Ltd. Hatch Medical will seek to sell or out-license Dr. Ward’s next generation drainage catheter fixation device, Cingo.

Dr. Ward, a specialist in vascular and interventional radiology, has developed the most advanced and patient-centric drainage catheter fixation device available today. We are delighted to be partnering with Fixit Medical to bring their exciting technology to the market,” said Paul Gianneschi, Managing Principal of Hatch Medical.

Image-guided percutaneous drainage has become the therapeutic treatment of choice for a wide variety of abnormal fluid collections such as abscesses and ascites, and is also widely used for the relief of renal and biliary obstruction. These procedures have resulted in reduced morbidity and mortality and have helped to reduce length of hospital stays and costs. A drainage catheter is generally inserted to accomplish this clinical outcome by an interventional radiologist, a physician who specializes in image-guided procedures.   The global interventional radiology drainage procedures market was valued at US$ 0.59 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2030.

Fixit Medical’s Cingo™ is the future of catheter fixation, featuring industry leading catheter fixation, durability and functionality. The device is produced out of a soft thermoplastic elastomer in two parts; a highly flexible base able to conform to curved anatomy with an integral housing and lid. There is an aperture within the base that accepts the drainage catheter and with the lid in place the device provides complete protection to the catheter, including a water-tight seal ideal for showering.

Cingo™ features best in class catheter fixation through a pull-force dissipating design and an estimated two-week wear time. Cingo™ also boasts a revolutionary design that protects catheters from twisting and kinking, provides easy access to the catheter exit site for improved visibility and cleaning, and includes an ingenious integral shower-safe feature.

The Cingo™ drainage catheter fixation technology is available for license, sale or partnering to interested third parties through an exclusive agreement with Hatch Medical.

Dr. Ward commented, “Hatch Medical is an ideal partner given their vast experience in the interventional radiology medical device market. We look forward to working with Hatch to identify a commercial partner committed to bringing the Cingo™ drainage catheter fixation device to market, so that patients and healthcare institutions can enjoy the benefits this game changing technology brings when compared to current fixation methods.”

Hot this week

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.